Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 22, 2003Current Opinion in Cardiology

Oral class III antiarrhythmics: what is new?

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with arrhythmias, particularly those with structural heart disease

Design

Review

Authors

MKMazhar H. KhanWayne State University

Discussion

Loading...

Member takes

Implication

Amiodarone warrants pacing preparedness in tachyarrhythmia patients; leaves open optimal class III selection in structural heart disease.

Structured PICO

P
Population
Patients with arrhythmias, particularly those with structural heart disease
I
Intervention
Oral class III antiarrhythmics (amiodarone, sotalol, dofetilide, azimilide, dronedarone)

This review highlights the evolving roles and safety profiles of oral class III antiarrhythmics in managing arrhythmias, particularly in patients with structural heart disease.

Cite This Study

Mazhar H. Khan (2003) studied this question.

synapsesocial.com/papers/6a74aa3696d04a2f43f54e09https://doi.org/10.1097/00001573-200401000-00010

Topics

Ventricular arrhythmias
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effects of Antiarrhythmic Drugs on Fibrillation in the Remodeled Atrium2003 · 161 citations
  2. 2Dofetilide: A new antiarrhythmic agent approved for conversionand/or maintenance of atrial fibrillation/atrial flutter2000 · 19 citations
  3. 3Amiodarone to Prevent Recurrence of Atrial Fibrillation2000 · 1,160 citations
  4. 4A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease2001 · 51 citations
  5. 5Cardioversion of atrial fibrillation with ibutilide: When is it most effective?2002 · 8 citations